Oxford Biomedica managed to reduce its loss in the first half of the year compared to the same period of the previous year as it increased revenue. Oxford Biomedica reported on Monday a first-half loss before tax of £35.74 million ($47.38 million), narrower than last year’s loss of £52.34 million. The narrower loss mainly reflected an increase in revenues and the ongoing impact of the 2023 restructure lowering the overall cost base. Loss per ordinary share was 30.88 pence, compared to a loss of 49.74 pence a year ago. Operating loss was £32.2 million, narrower than the loss of £50.7 million la…